A Study of IDRX-42 (GSK6042981) Versus (vs) Sunitinib in Participants With Gastrointestinal Stromal Tumors After Imatinib Therapy
This clinical trial is looking at a new medicine, called IDRX-42, to treat a type of cancer known as Gastrointestinal Stromal Tumours, or GIST for short. GIST affects the digestive system. This study is for adults whose GIST has either spread to other parts of the body or cannot be completely removed by surgery. Critically, everyone joining this study will have already been treated with another medicine called imatinib, and it either didn't work well enough or caused too many side effects. In this study, IDRX-42 will be compared to an existing treatment called sunitinib. Researchers want to find out if IDRX-42 is both effective and safe for patients, hoping it might offer a better treatment option for those living with GIST.
نظرة سريعة
ما هو موضوع هذه الدراسة؟
This study is comparing a new medication, IDRX-42, with an existing treatment called sunitinib, for people who have a type of cancer known as Gastrointestinal Stromal Tumours (GIST). GIST is a cancer that usually starts in the digestive system. The main goal of this research is to see if IDRX-42 is a good treatment option for patients, especially if their cancer has spread or can't be treated with surgery, and if they've already tried another drug called imatinib.
Researchers want to understand how well IDRX-42 works at shrinking or controlling the cancer, and also if it's safe to take. This kind of study helps doctors find new and better ways to treat cancer, giving patients more options in the future. By comparing it to an existing treatment, they can see if the new drug offers any advantages.
Taking part in a study like this is an important way for patients to get access to promising new treatments. It also helps the medical community learn more about GIST and develop effective therapies for everyone affected by it.
النقاط الرئيسية
- The study compares a new drug (IDRX-42) to an existing one (sunitinib) for GIST.
- It's for adults whose GIST has spread or can't be removed by surgery.
- Participants must have already tried the drug imatinib.
- The main goals are to check if IDRX-42 works well and is safe.
- Taking part helps doctors find better treatments for GIST.
- يمكنك التوقف عن المشاركة في أي وقت.
من قد يكون مؤهلاً؟
To join this study, you would need to be an adult, aged 18 or older.
Specifically, you must have a confirmed diagnosis of Gastrointestinal Stromal Tumours (GIST) that has either spread to other parts of your body or cannot be completely removed by surgery. It's also important that your GIST has continued to grow or caused problems even after you've been treated with the drug imatinib. The doctors will also need to review some tissue from your cancer, either from an old biopsy or by taking a new small sample.
There are also some reasons why you might not be able to join. For example, if you have cancer that has spread to your brain and isn't being treated, or if you've had a bad allergic reaction to similar drugs in the past. Also, if you have another type of cancer that has recently spread or needed active treatment, you might not be able to participate, unless it's a very common skin cancer or a very early-stage cancer that has been successfully removed.
هل يمكن أن تناسبك هذه الدراسة؟
أجب عن هذه الأسئلة السريعة لترى ما إذا كنت مؤهلاً. هذا دليل فقط - الفريق البحثي هو الذي يتخذ القرار النهائي.
- هل عمرك 18 سنة أو أكثر؟
- Do you have GIST that has spread or can't be surgically removed?
- Has your GIST progressed or caused problems after taking imatinib?
- Do you have a tissue sample (old or new) of your GIST available?
- Do you know if you have untreated cancer in your brain?
- Do you have any severe allergies to similar cancer medications?
ماذا يتضمن المشاركة؟
Taking part in this study would involve regular visits to the clinic for check-ups and to receive your study medication, which would be either IDRX-42 or sunitinib. You wouldn’t get to choose which one you receive. During these visits, the medical team will monitor your health, check how you're responding to the treatment, and look out for any side effects. This will involve regular blood tests, scans (like CT scans) to see how your GIST is responding, and assessments of your general well-being.
The study would last for a period of time decided by the doctors, which will include the treatment phase and a follow-up period to continue monitoring your health and the effects of the medication. The research team will explain all the details, including the schedule of visits and procedures, before you decide to join.
المخاطر والفوائد المحتملة
Locations (156)
- موقع التحقيق التابع لشركة GSKالرمز البريدي المؤكدفينيكس، الولايات المتحدة· التوظيف
- موقع التحقيق التابع لشركة GSKالرمز البريدي المؤكددوارتي، الولايات المتحدة· التوظيف
- موقع التحقيق التابع لشركة GSKالرمز البريدي المؤكدلا جولا، الولايات المتحدة· التوظيف
- موقع التحقيق التابع لشركة GSKالرمز البريدي المؤكدلوس أنجلوس، الولايات المتحدة· التوظيف
- موقع التحقيق التابع لشركة GSKالرمز البريدي المؤكدسان فرانسيسكو، الولايات المتحدة· التوظيف
- موقع التحقيق التابع لشركة GSKالرمز البريدي المؤكدسانتا مونيكا، الولايات المتحدة· التوظيف
- موقع التحقيق التابع لشركة GSKالرمز البريدي المؤكدUpland, United States· التوظيف
- موقع التحقيق التابع لشركة GSKالرمز البريدي المؤكدأورورا، الولايات المتحدة· التوظيف
- موقع التحقيق التابع لشركة GSKالرمز البريدي المؤكدنيو هيفن، الولايات المتحدة· التوظيف
- موقع التحقيق التابع لشركة GSKالرمز البريدي المؤكدواشنطن العاصمة، الولايات المتحدة· التوظيف
- موقع التحقيق التابع لشركة GSKالرمز البريدي المؤكدجاكسونفيل، الولايات المتحدة· التوظيف
- موقع التحقيق التابع لشركة GSKالرمز البريدي المؤكدميامي، الولايات المتحدة· التوظيف
أسئلة شائعة
What is GIST?
GIST stands for Gastrointestinal Stromal Tumours. It's a rare type of cancer that typically starts in the digestive system, most commonly in the stomach or small intestine.
What is imatinib?
Imatinib is a medicine often used as a first treatment for GIST. It works by blocking certain signals in cancer cells that help them grow.
What is sunitinib?
Sunitinib is another medicine used to treat GIST, especially if imatinib hasn't worked well enough or has caused too many side effects. It also targets pathways that help cancer cells grow.
Will I know if I'm getting the new drug or the old one?
In this type of study, participants are usually randomly assigned to receive either the new drug (IDRX-42) or the existing one (sunitinib). This is done by chance, like flipping a coin, so neither you nor your doctor will usually know which one you are receiving during your treatment, unless there's a medical reason to find out.
What are biomarkers?
Biomarkers are characteristics that can be measured to give an indication about your health or disease. In this study, they will look at cancer tissue to learn more about your GIST and how it might respond to treatments.
كيفية معرفة المزيد
مركز الاتصال للتجارب السريرية لشركة GSK في الولايات المتحدة
تحدث دائمًا إلى طبيبك العام أو الأخصائي قبل اتخاذ قرار بالمشاركة في دراسة.
هل أنت مهتم بالمشاركة؟
نقاش
مناقشة المجتمع
مدعوم من منتدانا في community.patient.info. يرجى التحلي بالاحترام — هذه ليست نصيحة طبية.